TG Therapeutics, Inc. (TGTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$55.99-1.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
TG Therapeutics grows BRIUMVI revenue from $161.7M to $204.9M in 2026-Q1. The company raised 2026 revenue guidance to about $892.5M. BRIUMVI expansion shows strong market demand. Operating expenses target $350M for 2026 to control costs.
The company missed earnings twice recently. Operating costs rose from $50.3M to $88.2M in one year. High costs could hurt profits and growth.
The price is about 46% above our fair value near $39. Analysts expect 46% revenue growth. Our view aligns with strong growth but notes cost risks.
Breaks if: BRIUMVI U.S. revenue drops below $150 million quarterly
TG Therapeutics is focused on expanding the BRIUMVI franchise through new formulations and market penetration.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, focusing on the potential of TGTX's BRIUMVI product. The current thesis state is intact, supported by strong recent financial performance despite ongoing earnings misses.
The market seems to have priced in a neutral valuation, with expectations that are not fully justified given the company's recent performance. TGTX is seen as cheap compared to peers, but there is an expectations gap that suggests some uncertainty.
Fundamentals may continue to show strong revenue growth from BRIUMVI, but there is a significant risk of missing earnings expectations in the near term. Management is stable and focused on advancing product development, although recent changes indicate mixed progress.
The long-term thesis hinges on the company's ability to maintain revenue growth and successfully advance BRIUMVI's development. Additionally, broader sector performance and economic conditions, such as job reports, will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report missed expectations significantly. This miss raises concerns about the company's future performance. There are no new supportive factors to offset this threat.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: BRIUMVI revenue falls below $600 million in FY26
Continue growing BRIUMVI U.S. net product revenue and total global revenue with raised full-year 2026 targets.
Stated as a priority in 4 of last 4 quarters. Total global revenue increased from $192.6 million in 2025-Q4 to $240.3 million in 2026-Q2, with BRIUMVI U.S. net product revenue rising from $182.7 million to $227.7 million over the same period. Management has consistently raised full-year 2026 revenue guidance, reflecting delivering growth trajectory.
“Raises full year 2026 total global revenue target to approximately $950 million and raises full year 2026 BRIUMVI U.S. net product revenue target to approximately $890 - 905 million”
“Raises full year 2026 total global revenue target to approximately $925 million and raises full year 2026 BRIUMVI U.S. net product revenue target to $885-900 million”
“Target guidance of approximately $875-900 million in total global revenue for 2026”
“Raises total global revenue target to approximately $585 million for the full year 2025”
Breaks if: Operating expenses exceed $400 million in FY26
Over the next 1 to 3 years, TGTX's performance will depend on its execution and sector dynamics. Not investment advice.